Ahead of the upcoming American Society of Hematology (ASH) annual meeting, Alex Niu, MD, of Roswell Park Comprehensive Cancer ...

Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label ...

Ahead of the upcoming American Society of Hematology annual meeting, a multicenter study published in the Journal of Clinical ...

Imaging spotted relapses for just a tiny fraction of patients with diffuse large B-cell lymphoma (DLBCL) before symptoms appeared, according to a new multi-institutional study, prompting ...

Further acknowledgement and study of the tumor microenvironment in diffuse large B-cell lymphoma (DLBCL) could eventually result in much more personalized—and effective—treatments. DLBCL being ...

Diffuse large B-cell lymphoma (DLBCL) grows fast, so you usually start treatment right away. The type you get depends on your overall health and stage of your cancer. For DLBCL, most people have ...

An expert gives an overview of current standard of care and what’s coming down the pipeline in terms of treatment options for diffuse large B-cell lymphoma. The development of new treatment options ...

Loretta J. Nastoupil, MD: Denise, do you have any advice for caregivers of someone who is about to head down the path of CAR-T [chimeric antigen receptor-T cell therapy] or considering it? Denise ...

Patients with diffuse large B-cell lymphoma whose tumors expressed PD-L1 experienced shorter OS than patients without PD-L1 expression, according to the results of a retrospective analysis.

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma In our understanding of molecular ...